Cargando…

Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a disease that leads to characteristic vascular wall remodeling and hemodynamic alterations. Consequently, this pulmonary vascular disease contributes to substantial morbidity and mortality in afflicted patients. PAH may be idiopathic in nature or associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Mirza, Shireen, Foley, Raymond J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412595/
https://www.ncbi.nlm.nih.gov/pubmed/22872790
http://dx.doi.org/10.4137/CCRPM.S8678
_version_ 1782239963654389760
author Mirza, Shireen
Foley, Raymond J.
author_facet Mirza, Shireen
Foley, Raymond J.
author_sort Mirza, Shireen
collection PubMed
description Pulmonary arterial hypertension (PAH) is a disease that leads to characteristic vascular wall remodeling and hemodynamic alterations. Consequently, this pulmonary vascular disease contributes to substantial morbidity and mortality in afflicted patients. PAH may be idiopathic in nature or associated with connective tissue disease, chronic liver disease, human immunodeficiency virus, congenital heart disease, and a growing list of other conditions. There are currently nine Food and Drug Administration-approved therapies for specific PAH treatment. Therapeutic targets include prostacyclin replacement, endothelin-1 antagonism, and phosphodiesterase-5 inhibition. This article focuses on the prostanoid treprostinil and explores its role in the management of patients with PAH.
format Online
Article
Text
id pubmed-3412595
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-34125952012-08-07 Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension Mirza, Shireen Foley, Raymond J. Clin Med Insights Circ Respir Pulm Med Review Pulmonary arterial hypertension (PAH) is a disease that leads to characteristic vascular wall remodeling and hemodynamic alterations. Consequently, this pulmonary vascular disease contributes to substantial morbidity and mortality in afflicted patients. PAH may be idiopathic in nature or associated with connective tissue disease, chronic liver disease, human immunodeficiency virus, congenital heart disease, and a growing list of other conditions. There are currently nine Food and Drug Administration-approved therapies for specific PAH treatment. Therapeutic targets include prostacyclin replacement, endothelin-1 antagonism, and phosphodiesterase-5 inhibition. This article focuses on the prostanoid treprostinil and explores its role in the management of patients with PAH. Libertas Academica 2012-07-24 /pmc/articles/PMC3412595/ /pubmed/22872790 http://dx.doi.org/10.4137/CCRPM.S8678 Text en © 2012 the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
spellingShingle Review
Mirza, Shireen
Foley, Raymond J.
Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension
title Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension
title_full Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension
title_fullStr Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension
title_full_unstemmed Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension
title_short Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension
title_sort clinical utility of treprostinil and its overall place in the treatment of pulmonary arterial hypertension
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412595/
https://www.ncbi.nlm.nih.gov/pubmed/22872790
http://dx.doi.org/10.4137/CCRPM.S8678
work_keys_str_mv AT mirzashireen clinicalutilityoftreprostinilanditsoverallplaceinthetreatmentofpulmonaryarterialhypertension
AT foleyraymondj clinicalutilityoftreprostinilanditsoverallplaceinthetreatmentofpulmonaryarterialhypertension